PrediSurge

PrediSurge is a France-based startup that specializes in developing a precision medicine platform for cardiovascular interventions. The company's slogan "Precision Medicine Platform for Cardiovascular Interventions" reflects its core focus. PrediSurge's technology leverages pre-operative imaging to create patient-specific digital twins, which simulate arteries and valves' biomechanical behavior. This innovative approach assists physicians in better planning their endovascular interventions. The startup's platform serves both clinical and industrial contexts. In a clinical setting, the digital models facilitate the investigation of different device implantation approaches, optimizing strategies for individual patients. Meanwhile, in an industrial context, the use of digital twins accelerates product development, reduces design iteration periods, and predicts in-vivo performances early on. PrediSurge's solution is a cost-effective means to test multiple medical device designs in-silico at various stages of the development process. Established in 2017, PrediSurge recently bagged a significant €6.50M Series A investment on 16 October 2023. The consortium of investors backing this round includes LIFTT, The European Innovation Council, UI Investissement, Saint Victor Capital, and Crédit Agricole Lhl Capital Innovation. With its focus on enhancing procedures planning and medical device designs, PrediSurge aims to make endovascular procedures even safer for patients. The company operates in the intersection of the Health Care and Information Technology industries, positioning itself at the forefront of advancing precision medicine in cardiovascular care.